Werewolf Therapeutics Inc (NAS:HOWL) Stock News, Headlines & Updates
Werewolf Therapeutics Inc Stock News from GuruFocus
- 1
Jun 01, 2024
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
GlobeNewswire • 11:00am
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
Marketwired • 8:00am
May 30, 2024
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
Marketwired • 7:00am
May 23, 2024
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
Marketwired • 4:00pm
May 03, 2024
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Marketwired • 6:00am
Apr 24, 2024
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Marketwired • 10:00am
Apr 23, 2024
- 1
Show
Entries
Headlines
Total 0- 1
No recent news